News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,716 Results
Type
Article (39997)
Company Profile (249)
Press Release (664469)
Multimedia
Podcasts (58)
Webinars (14)
Section
Business (204273)
Career Advice (2011)
Deals (35454)
Drug Delivery (95)
Drug Development (81131)
Employer Resources (172)
FDA (16245)
Job Trends (14886)
News (345487)
Policy (32604)
Tag
Academia (2556)
Accelerated approval (9)
Adcomms (22)
Allergies (95)
Alliances (49569)
ALS (108)
Alzheimer's disease (1437)
Antibody-drug conjugate (ADC) (151)
Approvals (16243)
Artificial intelligence (307)
Autoimmune disease (28)
Automation (18)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (120)
Biotechnology (175)
Bladder cancer (93)
Brain cancer (33)
Breast cancer (363)
Cancer (2847)
Cardiovascular disease (209)
Career advice (1681)
Career pathing (30)
CAR-T (183)
CDC (30)
Cell therapy (494)
Cervical cancer (22)
Clinical research (66825)
Collaboration (1011)
Company closure (3)
Compensation (680)
Complete response letters (21)
COVID-19 (2624)
CRISPR (56)
C-suite (321)
Cystic fibrosis (111)
Data (2972)
Decentralized trials (2)
Denatured (20)
Depression (58)
Diabetes (346)
Diagnostics (6421)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (135)
Drug pricing (120)
Drug shortages (28)
Duchenne muscular dystrophy (124)
Earnings (87436)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (113717)
Executive appointments (845)
FDA (17884)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (925)
Gene editing (129)
Generative AI (22)
Gene therapy (371)
GLP-1 (777)
Government (4499)
Grass and pollen (4)
Guidances (181)
Healthcare (18839)
Huntington's disease (30)
IgA nephropathy (39)
Immunology and inflammation (146)
Immuno-oncology (8)
Indications (39)
Infectious disease (2795)
Inflammatory bowel disease (147)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (119)
Interviews (312)
IPO (16592)
IRA (44)
Job creations (3636)
Job search strategy (1424)
Kidney cancer (13)
Labor market (52)
Layoffs (491)
Leadership (18)
Legal (7929)
Liver cancer (79)
Lung cancer (399)
Lymphoma (207)
Machine learning (11)
Management (58)
Manufacturing (380)
MASH (90)
Medical device (13456)
Medtech (13461)
Mergers & acquisitions (19574)
Metabolic disorders (844)
Multiple sclerosis (97)
NASH (16)
Neurodegenerative disease (113)
Neuropsychiatric disorders (31)
Neuroscience (2107)
NextGen: Class of 2025 (6516)
Non-profit (4488)
Now hiring (47)
Obesity (424)
Opinion (217)
Ovarian cancer (100)
Pain (104)
Pancreatic cancer (120)
Parkinson's disease (186)
Partnered (22)
Patents (295)
Patient recruitment (160)
Peanut (50)
People (57676)
Pharmaceutical (63)
Pharmacy benefit managers (21)
Phase I (20826)
Phase II (29437)
Phase III (21902)
Pipeline (1618)
Policy (197)
Postmarket research (2563)
Preclinical (8864)
Press Release (64)
Prostate cancer (139)
Psychedelics (35)
Radiopharmaceuticals (253)
Rare diseases (454)
Real estate (5917)
Recruiting (66)
Regulatory (22615)
Reports (50)
Research institute (2324)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (8)
RSV (49)
Schizophrenia (86)
Series A (155)
Series B (106)
Service/supplier (11)
Sickle cell disease (60)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3587)
State (2)
Stomach cancer (14)
Supply chain (75)
Tariffs (57)
The Weekly (36)
Vaccines (777)
Venture capital (53)
Weight loss (254)
Women's health (45)
Worklife (16)
Date
Last 7 days (365)
Last 30 days (1765)
Last 365 days (31173)
2025 (16612)
2024 (35218)
2023 (40076)
2022 (51174)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32110)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (720)
Alabama (61)
Alaska (7)
Arizona (243)
Arkansas (13)
Asia (38197)
Australia (6231)
California (7400)
Canada (2349)
China (668)
Colorado (320)
Connecticut (316)
Delaware (192)
Europe (82085)
Florida (1114)
Georgia (247)
Hawaii (1)
Idaho (59)
Illinois (636)
India (26)
Indiana (360)
Iowa (16)
Japan (226)
Kansas (108)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1019)
Massachusetts (5501)
Michigan (245)
Minnesota (448)
Mississippi (3)
Missouri (89)
Montana (28)
Nebraska (25)
Nevada (80)
New Hampshire (66)
New Jersey (2066)
New Mexico (28)
New York (2081)
North Carolina (1076)
North Dakota (8)
Northern California (3258)
Ohio (235)
Oklahoma (16)
Oregon (34)
Pennsylvania (1608)
Puerto Rico (17)
Rhode Island (36)
South America (1098)
South Carolina (34)
South Dakota (1)
Southern California (2763)
Tennessee (125)
Texas (1114)
United States (27446)
Utah (219)
Virginia (182)
Washington D.C. (72)
Washington State (629)
West Virginia (4)
Wisconsin (65)
704,716 Results for "anaptysbio inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it has appointed John Orwin chairman of the AnaptysBio Board of Directors.
September 18, 2023
·
5 min read
Biotech Beach
AnaptysBio Announces Participation in Upcoming June 2023 Investor Conferences
AnaptysBio, Inc. announced that Daniel Faga, interim president and chief executive officer of AnaptysBio, and other members of its senior management team are scheduled to participate in both of the upcoming investor conferences below:
May 30, 2023
·
3 min read
Biotech Beach
AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, and Dr. Paul Lizzul, chief medical officer, will present at the Stifel 2023 Immunology and Inflammation Virtual Summit later this month.
September 12, 2023
·
3 min read
Business
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the second quarter ended June 30, 2023 and provided a business update.
August 7, 2023
·
11 min read
Drug Development
AnaptysBio Touts Positive Top-Line Phase III Data for Pustular Psoriasis Candidate
The company’s experimental lgG4 antibody met the primary endpoint in a late-stage study of the rare skin disease. AnaptysBio will submit an application to the FDA by the third quarter of 2024.
October 16, 2023
·
2 min read
·
Matt Olszewski
Business
AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
AnaptysBio, Inc., a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced the appointment of Rita Jain, M.D., to the company’s Board of Directors, effective immediately.
April 6, 2023
·
5 min read
Business
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the first quarter ended March 31, 2023 and provided pipeline updates.
May 11, 2023
·
10 min read
Deals
AnaptysBio Announces Stock Repurchase Plan
AnaptysBio, Inc. today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $50,000,000 of the Company’s outstanding common stock, par value $0.001 per share.
January 13, 2023
·
3 min read
Biotech Beach
AnaptysBio to Participate in Upcoming November 2022 Investor Conferences
AnaptysBio, Inc. announced that Dan Faga, chief executive officer of AnaptysBio, will represent the company in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Conference on Monday November 14th, 2022, at 1:00 p.m. ET / 10:00 a.m.
November 9, 2022
·
1 min read
Biotech Beach
AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference
AnaptysBio, Inc. announced that Dan Faga, interim president and chief executive officer, will present at the Cowen and Company 43rd Annual Health Care Conference on Monday, March 6, 2023, at 2:50 p.m. ET / 11:50 a.m. PT.
February 27, 2023
·
1 min read
1 of 70,472
Next
